bioRxivCancer BiologyPreprint
Fatty acid scavenging enables cancer escape from KRAS inhibition
Zihang YuaniD, Bo LiniD, Chunlan WangiD, Yingying Miao, Da Zhang, Ziru Meng, Gangqi WangiD, Andrew M. LowyiD, Michael KariniD, F Y YangiD, Beicheng SuniD, Hua SuiD
Abstract
Although inhibitors of oncogenic KRAS have shown clinical efficacy1, resistance to KRAS inhibition is common2, and its molecular basis remains unclear. Here we show that KRASi-resistant cancer cells sustain mitochondrial bioenergetics through enhanced fatty acid (FA) metabolism, despite suppression of canonical KRAS signaling. Specifically, KRASi-resistant pancreatic cancer cells exploit macropinocytosis to scavenge FA released from adipose tissue, fueling beta-oxidation independently of KRAS-PI3K signaling. This adaptive metabolic program is driven by the adhesion G protein-coupled receptor ADGRB1, which activates non-canonical PI3K{gamma}-PAK1 signaling to stimulate macropinocytosis and maintain metabolic homeostasis under KRASi. Disruption of ADGRB1-PI3K{gamma} signaling dismantles this metabolic program and restores KRASi sensitivity. This pathway operates across multiple KRAS-mutated cancers and is associated with poor therapeutic response and outcome. These findings offer a promising strategy for overcoming KRASi resistance.
- organism: human
- assay: metabolomics
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma
Garima Baral, Claire M. Pfeffer, … Brittany L. Allen-Petersen·bioRxiv·Jul 14, 2025
- Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition
Xiangyu Ge, Jaffarguriqbal Singh, … Mandar Deepak Muzumdar·bioRxiv·Jun 20, 2025
- Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations
Philipp Hafner, Steffen Johannes Keller, … Dietrich Alexander Ruess·Signal Transduction and Targeted TherapyPeer-reviewed·Jan 16, 2026
- Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance
Vishnu Muthuraj Kumarasamy, Jianxin Wang, … Erik S. Knudsen·Cancer ResearchPeer-reviewed·Oct 2, 2026
- Induced ERBB response and standing FAK dependency nominate separable KRAS-combination hypotheses in pancreatic cancer
Jake Y. Chen, Ehsan Saghapour, … Zhandos Sembay·bioRxiv·Jul 10, 2026
- Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers
Madelaine Skolastika Theardy, Mitsunobu Takeda, … Wantong Yao·Cell Reports MedicinePeer-reviewed·Jul 25, 2025